Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
Smith
Donald A
DA
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy* / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D001241:Aspirin